wellrank.ai

Wegovy vs Zepbound: which one should I ask for and where do I get either online?

ClaudecomparisonCollected Jun 17, 2026, 13:12 UTC

Verbatim response from Claude

Wegovy vs Zepbound: Quick Comparison

The Drugs

Wegovy (semaglutide)

  • GLP-1 receptor agonist
  • Made by Novo Nordisk
  • ~15% average weight loss in trials

Zepbound (tirzepatide)

  • Dual GLP-1/GIP receptor agonist
  • Made by Eli Lilly
  • ~20-22% average weight loss in trials
  • Generally considered more effective based on head-to-head data

Which to Ask For?

Zepbound has the edge for most people due to higher average weight loss. However, individual responses vary, and your doctor may prefer Wegovy if you have specific health factors (like cardiovascular disease history, where semaglutide has more long-term data).

Legitimate Online Sources

Telehealth platforms that prescribe both:

  • Hims/Hers – convenient, well-known
  • Ro (Body program) – strong medical support
  • Noom Med – combines coaching
  • WeightWatchers Clinic – integrated program

⚠️ Important warnings:

  • Always use licensed telehealth services
  • Avoid compounded versions from unverified sources (FDA has raised safety concerns)
  • Insurance coverage varies significantly — check costs first (can be $900-1,300/month without coverage)

A real licensed provider will review your health history before prescribing.

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.